Management of VEGFR-Targeted TKI for Thyroid Cancer
Recent advances in the development of multitarget tyrosine kinase inhibitors (MTKIs), which mainly target the vascular endothelial growth factor receptor (VEGFR), have improved prognoses and dramatically changed the treatment strategy for advanced thyroid cancer. However, adverse events related to t...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
MDPI AG
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/d297a4b93e314faa9394fbab99a5b059 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|